Since targeted NGS allows to screen the entire EGFR exon and because of its high analytical sensitivity we have identified in our series three uncommon mutations (T785I, F795S, V845M) that have been previously reported in lung carcinoma or in other tumors types, the clinical relevance of which is currently undefined [62-66]. The gene discussed is EGFR; the disease is lung carcinoma.